Appetite-Inducing Hormone Receptor Found Active in Breast Cancer
The UC research team, led by Hassane Amlal, PhD, and Sulaiman Sheriff, PhD, report their laboratory findings on the hormone, neuropeptide Y, and its receptor in the April edition of the journal Cancer Research.
Earlier studies have shown that neuropeptide Ys receptor, known as Y1, is overproduced in human ovarian, prostate and breast cancers. This study, however, is the first to demonstrate that the Y1 receptor is actually working in breast cancer cells and can be turned on by excessive estrogena known cause of about 60 to 70 percent of breast cancers, they say.
The high incidence and activity of the Y1 receptor in human breast tumor cells suggests that it may play an important role in breast cancer, explains Dr. Sheriff, a UC research assistant professor in the department of surgery.
Pilot data suggests that about 40 percent of all breast cancer patients have increased levels of the Y1 receptor, he says.
We knew this receptor was overproduced in breast cancer tissue, adds Dr. Amlal, a research assistant professor in the department of internal medicine, but now the real question is what does it do in breast cancer cells, and how can we use it as a target to fight cancer.
The UC researchers were able to slow the growth of breast cancer cells with abnormally high levels of the Y1 receptor by treating them with neuropeptide Y hormone produced by chemical synthesis.
This finding gives us a promising new investigational target in the fight against breast cancer, the authors report. If we can find a way to selectively activate the Y1 receptor, we can limit breast cancer growth in the body.
Further studies of the Y1 receptors role, they explain, may ultimately lead to more targeted drug therapy for many breast cancer patients.
According to the American Cancer Society, more than 214,000 women and men will be diagnosed with breast cancer in 2006. About 19 percent will die from the disease.
This study was sponsored by UC and the National Institutes of Health. The research team also included Somia Faroqui, and Ambikaipakan Balasubramaniam, PhD.
Tags
Related Stories
UC radiation oncologist speaks with Local 12 news about clinical trial for head and neck cancer treatment
August 10, 2026
Dr. Sara Medek, a UC radiation oncology professor, speaks with Local 12 news about a new clinical trial aimed at reducing radiation in certain areas while still treating cancer effectively but with fewer painful side effects.
Cancer Center director charts future based on collaboration, AI
August 10, 2026
David Gius, MD, PhD, was featured in a Cincinnati Business Courier article and The Cancer Letter’s “The Directors" podcast discussing his priorities and goals as he recently took the helm as director of the University of Cincinnati Cancer Center.
Bidirectional link between oral, kidney health calls for patient education, access
August 4, 2026
Despite growing awareness of the connection between oral health and chronic health conditions, patient awareness and access to dental care remain limited, according to University of Cincinnati experts who recently spoke with Healio | Nephrology News & Issues.